Publicaciones en colaboración con investigadores/as de Essen University Hospital (12)

2018

  1. Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

    JCI insight, Vol. 3, Núm. 23

2016

  1. Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma

    Oncotarget, Vol. 7, Núm. 2, pp. 1960-1972

2014

  1. CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients

    PLoS ONE, Vol. 9, Núm. 12

  2. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma

    Pediatric Blood and Cancer, Vol. 61, Núm. 10, pp. 1867-1870

2013

  1. Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes

    PLoS ONE, Vol. 8, Núm. 1

2012

  1. Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome

    British Journal of Cancer, Vol. 107, Núm. 8, pp. 1409-1417

  2. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers

    Genome Biology, Vol. 13, Núm. 10

  3. Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas

    International Journal of Cancer, Vol. 130, Núm. 11, pp. 2599-2606

2011

  1. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples

    Clinical Cancer Research, Vol. 17, Núm. 24, pp. 7684-7692

2010

  1. An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours

    Oncogene, Vol. 29, Núm. 24, pp. 3583-3592

  2. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors

    Oncogene, Vol. 29, Núm. 9, pp. 1394-1404

  3. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

    Clinical Cancer Research, Vol. 16, Núm. 17, pp. 4353-4362